Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 AntibodyV. Ellen Maher, Richard Pazdur, Laura L. Fernandes et al.|Journal of Clinical Oncology|2019Cited by 348
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L. Suzman, Julia A. Beaver, Sundeep Agrawal et al.|The Oncologist|2018Cited by 200
Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval SummaryPaul G. Kluetz, Richard Pazdur, Wei Chen et al.|Clinical Cancer Research|2013Cited by 171
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker AnalysisJames Xu, Richard Pazdur, V. Ellen Maher et al.|The Oncologist|2017Cited by 151
Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval SummaryKatherine A. Thornton, Richard Pazdur, Geoffrey Kim et al.|Clinical Cancer Research|2012Cited by 149